- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency - BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the publication of a paper titled, "Phenotypic characterization of ENPP1 deficiency: gen

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET. A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme's website under events, where a replay of the event will also be available for a limited time. About Inozyme PharmaInozyme Pharma is

- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease - BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:I

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET. A live webcast of the presentation can be accessed from the Investor Relations section of Inozyme's website under events, where a replay of the event will also be available for a limited time. About Inozyme Pharma Inozyme Pharma is a pioneering clinical-stage b

BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida. Presentation Details: Title: Impact of the Enzyme Replacement Therapy, INZ-701, in Children with ENPP1 Deficiency:

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia, with no radiographic evidence of rickets – - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; on track to complete dosing in January 2026, with topline data to follow in early 2026 – - Regulatory guidance from FDA and EMA supports planned ASPIRE pivotal trial focused on addressing severe complications of ABCC6 Deficiency in children – BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET. A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme's website under events, where a replay of the event will also be available for a limit

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences: The Stifel 2024 Healthcare Conference. The presentation will take place on Monday, November 18 from 3:35-4:05pm ET.The Jefferies London Healthcare Conference. The presentation will take place on Wednesday, November 20 from 2:30-2:55pm GMT / 9:30-9:55am ET. A live webcast of the presentations can be accessed from the Investor

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical c

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD - - Company plans to initiate a registrational trial in calciphylaxis in 2025 subject to regulatory alignment and sufficient funding - BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced positive interim data from its

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

3 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

SCHEDULE 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

S-8 - Inozyme Pharma, Inc. (0001693011) (Filer)

10-K - Inozyme Pharma, Inc. (0001693011) (Filer)

8-K - Inozyme Pharma, Inc. (0001693011) (Filer)

SCHEDULE 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

8-K - Inozyme Pharma, Inc. (0001693011) (Filer)

10-Q - Inozyme Pharma, Inc. (0001693011) (Filer)

8-K - Inozyme Pharma, Inc. (0001693011) (Filer)

8-K - Inozyme Pharma, Inc. (0001693011) (Filer)

8-K - Inozyme Pharma, Inc. (0001693011) (Filer)

Raymond James initiated coverage of Inozyme Pharma with a rating of Outperform and set a new price target of $26.00

Stifel initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $16.00

Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

Wells Fargo initiated coverage of Inozyme Pharma with a rating of Overweight and set a new price target of $14.00

Jefferies upgraded Inozyme Pharma from Hold to Buy and set a new price target of $6.00 from $4.50 previously

Jefferies initiated coverage of Inozyme Pharma with a rating of Hold and set a new price target of $5.00

HC Wainwright & Co. initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $33.00

Needham initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $23.00

- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time. During the conference call and webcast, the Company will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), and

- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the t

BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY)("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time. During the webcast and conference call, members of Inozyme management will review interim data from the Phase 2 portion of the ongoing trial of INZ-701 in adult patients with ENPP1 Deficiency. The Company will also provide an update on the safety and pharmacodynamic data from the ongoing Phase 1/2 tri

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in pediatric patients expected to initiate in October 2023, topline data expected to be reported in mid-2025 - - Updated cash runway expected to fund cash flow requirements into Q1 2025 - - Company to host conference call today at 8am ET - BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation

– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call to provide an update on the Company's ENPP1 Deficiency program on July 26, 2023, at 8am ET. During the call, members of Inozyme management will provide an overview of the Company's global development strategy for INZ-701 in patients with ENPP1 Deficiency, including the advancement of INZ-701 in infants an

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency. "Initiation of the ENERGY-1 trial in infants is an important milestone as we continue to advance INZ-701 with the goal of improving the lives of patients with ENPP1 Deficiency across all age groups. We are committed to a global program to identify and treat all newborns with this condition," said Kurt Gunter, M.D., seni

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in highest dose cohort in ABCC6 Deficiency (PXE) trial - - INZ-701 was generally well-tolerated and exhibited a favorable safety profile in both trials - - Company updates its cash runway guidance to fund cash flow requirements into fourth quarter of 2024 - - Company to host virtual investor and analyst event at 8:00 a.m. ET on February 16, 2023 - BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Inozyme Pha

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) – BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Thursday, Feb. 16, 2023 at 8 a.m. ET. During the webcast and conference call members of Inozyme management will review topline pharmacokinetic, pharmacodynamic (PK/PD), and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 D